This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Lyell Immunopharma’s 8K filing here.
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
See Also
- Five stocks we like better than Lyell Immunopharma
- What is a Special Dividend?
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- ESG Stocks, What Investors Should Know
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
